Positive Recommendations made by the PBAC - April 2008

PDF Printable version this page (PDF 19 KB)

Positive Recommendations made by the PBAC - April 2008

Drug and Form

Drug Use and Type

Listing Requested

PBAC Recommendation

INFLUENZA VACCINE, injection (trivalent) containing A/Solomon Islands/3/2006, A/Brisbane/10/2007 and B//Florida/4/2006 like strains, 0.25 mL pre-filled syringe, Fluvax Junior® CSL Biotherapies Pty Ltd

Minor submission
Influenza vaccination Restricted benefit listing for children up to 35 months of age at increased risk of adverse consequences from infections of the lower respiratory tract. The PBAC recommended listing of this additional form of influenza vaccine suitable for children up to 35 months of age.
MELOXICAM, tablets, 7.5 mg and 15 mg, Chem mart Meloxicam®, Chem mart Pty Ltd, GenRx Meloxicam®, Apotex Pty Ltd, Meloxibell®, Meloxicam-GA®, Bellwether Pharma Pty Ltd, Meloxicam Ranbaxy®, Ranbaxy Australia Pty Ltd, Meloxicam Sandoz®, Sandoz Pty Ltd, Movalis 7.5® and Movalis 15®, Arrow Pharmaceuticals Pty Ltd, Moxicam 7.5® and Moxicam 15®, Alphapharm Pty Ltd, Pharmacor Meloxicam 7.5® and Pharmacor Melxoicam 15®, Pharmacor Pty Ltd, Terry White Chemists Meloxicam 7.5 mg® and Terry White Chemists Meloxicam 15 mg®, Terry White Chemists, Mobic®, Boehringer Ingelheim Pty Ltd, capsules, 7.5 mg and 15 mg, Mobic® Boehringer Ingelheim Pty Ltd

Minor submission
Arthritis Restricted benefit listing for the 
symptomatic treatment of rheumatoid arthritis
The PBAC recommended extending the listing of meloxicam to include the symptomatic treatment of rheumatoid arthritis.